Highlights

• Net Revenue of $352.7 million, up 10.9% year over year and 3.6% from the second quarter

• International revenue up about 28% to $58.7 million; adjusted EBITDA of $77.6 million at a 22.0% margin

• Net loss from continuing operations of $37.4 million; Debt of $636.9 million against cash of $104.9 million

Curaleaf Holdings, Inc. (TSX:CURA) reported its third quarter results in a release issued on Tuesday of last week, followed by a conference call that evening. The Stamford, Connecticut based operator, which also trades on the OTCQX in the United States, said net revenue reached a record for the company, helped by a faster pace of international growth and by new dispensaries in its home markets.

Headline Numbers From the Quarter

All amounts in the release are in United States dollars. Net revenue for the three months ended in September was about three hundred fifty-three million dollars, up roughly eleven percent from the same period last year and up a little under four percent from the second quarter. Domestic sales were near two hundred ninety-four million dollars, while international sales were about fifty-nine million dollars.

Gross profit was about one hundred seventy and a half million dollars, a Margin of about forty-eight percent, which management reported as lower than a year earlier by a little more than two percentage points. Adjusted EBITDA was about seventy-eight million dollars, equal to a margin of twenty-two percent, a slight decline compared with the prior year. The company recorded a net loss from continuing operations of roughly thirty-seven million dollars, or fourteen cents per share, despite the revenue gain.

Nine Month Perspective

Over the first nine months of the year, net revenue totalled just above one billion dollars, up about nine percent. Adjusted EBITDA for that period was about two hundred eleven million dollars at a margin of nearly twenty-one percent. Net Income from continuing operations for the nine months was positive at about forty-five million dollars, so the third quarter loss followed a stronger first half.

The pattern points to a Business that is growing sales steadily while margins compress modestly. Compression of that kind is common across the sector as operators absorb price competition, higher promotional spending and the mix effect of newer, lower-priced products. Capital Expenditure for the nine months was about fifty million dollars, leaving free Cash Flow from continuing operations at roughly twenty-two million dollars.

The International Engine

The international segment was the fastest growing part of the business, up about twenty-eight percent. Curaleaf distributes cannabis products across Europe, Canada and Australasia, and the release noted that the first two standardized cannabis preparations were registered in Spain during the quarter. Medical cannabis markets in Europe have expanded as several governments adjust their frameworks, and a business with established pharmaceutical-grade Supply chains can benefit from that shift.

Readers following Cannabis Stocks will recognise that the most volatile part of the thesis for North American operators has been how quickly regulated international markets scale. Cross-border shipments depend on licensing, quality standards and Import permits, so growth can be uneven from one quarter to the next. A single large customer or a delayed permit can move quarterly figures noticeably.

Dispensary Footprint and Federal Registrations

The company operated or managed one hundred eighty-eight dispensaries at the end of the quarter, rising to one hundred ninety-one after quarter end. Its Florida network reached seventy-eight locations and then eighty after two further openings, one in Port Orange and one in Wellington. Three dispensaries were also relocated during the period.

After quarter end, the company acquired the Equity interest in a New Jersey operator, Boone Town Provisions, and began receiving registrations from the United States Drug Enforcement Administration for medical marijuana dispensaries. Those registrations relate to the federal reclassification process that has become a focal point for investors, since lower federal scheduling could eventually change tax treatment and banking access. The release did not claim that the registrations alter near-term earnings.

The company also noted its addition to a major Canadian all-capitalization index during the quarter, a development that can broaden the base of institutional holders who track such benchmarks.

Cash, Debt and Capital Allocation

Cash and equivalents at quarter end were about one hundred five million dollars, including roughly twelve and a half million dollars of restricted cash. Outstanding debt, net of discounts and financing fees, was about six hundred thirty-seven million dollars. Operating Cash Flow from continuing operations in the quarter was about twenty-two million dollars, which management attributed to timing differences that it expects to reverse in the next quarter. The target for full-year operating cash flow remains about one hundred fifty million dollars.

The company continued modest share repurchases, retiring a little over one hundred thousand shares for about one million dollars in the quarter and a little over one million shares for roughly eight million dollars so far this year. Relative to the size of the debt balance and the market capitalization, those repurchases are small, but they signal an intention to return capital while funding expansion.

Strategic Context and Open Items

The release also referred to a pending offer the company has made for a Canadian licensed producer, an offer that had been enhanced in October and that management said it was still evaluating in light of an alternative transaction announced by the target. The release did not set out a final decision, and the outcome depends on shareholder, board and regulatory processes that remain unresolved.

Chief executive and chairman Boris Jordan described the goal as building the global leader in cannabis and cited resilient consumer Demand despite pressure on household budgets. Canadian households face their own affordability pressures as the Bank of Canada balances Inflation against slower growth, which affects discretionary categories including legal cannabis.

What to Watch Next

The next reporting period will test several assumptions embedded in the current results.

Key variables include whether margins stabilise as new stores mature, whether the timing-related cash flow shortfall reverses as management expects, and how the international business scales. Interest costs on the debt balance will also influence net income, and the path of United States federal policy remains an external Factor that could alter the competitive environment.

The shares are listed on the Toronto Stock Exchange, and the company was added to a broad Canadian equity benchmark during the quarter. Cannabis names carry a very small weight in the [S&P/TSX Composite Index], so that benchmark's moves rarely explain the stock's behaviour. Instead, trading in the sector tends to follow policy headlines, regulatory milestones, Merger activity and quarterly results rather than domestic economic data alone.

Investors and analysts will also pay attention to the audited annual statements, the evolution of pricing in the largest state markets, and any further disclosure on dispensary openings, since new stores typically dilute margins during their first year before maturing. Those details, together with the cash flow Reversal management has projected, will shape how the third quarter is viewed in hindsight.